Trial Profile
An Open Label, Multicentre Study to Evaluate Patient Satisfaction With Fluticasone/Salmeterol HFA MDI With Counter in Adult Subjects (18 Years of Age and Older) With Asthma or COPD.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 20 May 2009 Actual initiation date changed from Dec 2006 to Jan 2007 as reported by ClinicalTrials.gov.
- 26 Apr 2008 New trial record.